Related Experiment Video

Updated: Jun 24, 2026

Generalized Psychophysiological Interaction (PPI) Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
09:38

Generalized Psychophysiological Interaction (PPI) Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease

Published on: November 14, 2017

Apolipoprotein E gene polymorphism and obesity status in middle-aged men with coronary heart disease

Genovefa D Kolovou1, Katherine K Anagnostopoulou, Peggy Kostakou

  • 1First Cardiology Department, Onassis Cardiac Surgery Center, Athens, Greece. genovefa@kolovou.com

In Vivo (Athens, Greece)
|April 17, 2009
PubMed

Insights

Apolipoprotein E (apoE) genotype influences coronary heart disease (CHD) risk across different body mass index (BMI) categories. The epsilon2 allele, linked to heart protection, was less common in normal-weight CHD patients.

Area of Science:

  • Genetics
  • Cardiology
  • Metabolic Health

Background:

  • Apolipoprotein E (apoE) gene polymorphism is linked to coronary heart disease (CHD) and obesity.
  • Investigating the relationship between apoE polymorphism and CHD across varying body mass index (BMI) levels is crucial.

Purpose of the Study:

  • To examine the association between apoE gene polymorphism and CHD in individuals with different BMI.
  • To understand how apoE genotype influences CHD risk in normal-weight, overweight, and obese patients.

Main Methods:

  • Genotyping of apoE polymorphism was performed on 359 men with CHD and 248 healthy controls (BMI <27 kg/m2).
  • CHD patients were stratified into normoweight (BMI: 24±1 kg/m2), overweight (BMI: 27±1 kg/m2), and obese (BMI: 32±2 kg/m2) groups.

Main Results:

  • Significant differences in apoE genotype frequencies were observed between normoweight CHD patients and healthy controls.
  • The frequency of apoE epsilon3epsilon4 + epsilon4epsilon4 genotypes was higher in obese CHD patients compared to normoweight CHD patients (p=0.043).
  • CHD severity was comparable across all patient groups, irrespective of BMI or apoE genotype.

Conclusions:

  • Normoweight CHD patients, despite lower BMI and better lipid profiles, showed no significant difference in CHD severity.
  • A lower frequency of the cardio-protective apoE epsilon2 allele in normoweight CHD patients may partially explain these findings.
  • Apolipoprotein E genotype plays a role in CHD risk, even in individuals with normal weight.
Abstract

More Related Videos

Sample Preparation to Bioinformatics Analysis of DNA Methylation: Association Strategy for Obesity and Related Trait Studies14:56

Sample Preparation to Bioinformatics Analysis of DNA Methylation: Association Strategy for Obesity and Related Trait Studies

Published on: May 6, 2022

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in adipocytes...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Human Genetics01:28

Human Genetics

Human genetics provides a profound framework for understanding the interplay between genetic predispositions and human psychology. At the heart of this discipline lies the study of how genes influence physical traits, behaviors, and susceptibility to diseases. Each person carries a unique genetic code that subtly or significantly shapes their psychological and behavioral landscape.
The complex relationship between genetics and psychology is observable through common biological components such...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...